[
    [
        {
            "time": "",
            "original_text": "天坛生物：公司所属武汉血制获得临床批件的“静注COVID-19人免疫球蛋白”系采用经疫苗免疫的健康人血浆，并经抗体效价筛选合格制备而得，目前处于临床试验准备阶段",
            "features": {
                "keywords": [
                    "天坛生物",
                    "武汉血制",
                    "临床批件",
                    "静注COVID-19人免疫球蛋白",
                    "疫苗免疫",
                    "抗体效价",
                    "临床试验"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "天坛生物：公司所属武汉血制获得临床批件的“静注COVID-19人免疫球蛋白”系采用经疫苗免疫的健康人血浆，并经抗体效价筛选合格制备而得，目前处于临床试验准备阶段",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]